56 related articles for article (PubMed ID: 10641573)
1. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model.
Shapira MY; Hirshfeld E; Weiss L; Zeira M; Kasir J; Or R; Resnick IB; Slavin S
Cancer Immunol Immunother; 2005 Apr; 54(4):383-8. PubMed ID: 15692848
[TBL] [Abstract][Full Text] [Related]
2. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.
Weiss L; Weigensberg M; Morecki S; Bar S; Cobbold S; Waldmann H; Slavin S
Cancer Immunol Immunother; 1990; 31(4):236-42. PubMed ID: 2379219
[TBL] [Abstract][Full Text] [Related]
3. Linomide administration following bone marrow transplantation in mice.
Weiss L; Abdul-Hai A; Shufaro Y; Reich S; Slavin S
Cancer Immunol Immunother; 2002 Dec; 51(11-12):596-602. PubMed ID: 12439604
[TBL] [Abstract][Full Text] [Related]
4. Lack of IL-21 signal attenuates graft-versus-leukemia effect in the absence of CD8 T-cells.
Meguro A; Ozaki K; Hatanaka K; Oh I; Sudo K; Ohmori T; Matsu H; Tatara R; Sato K; Sakata Y; Nakae S; Leonard WJ; Ozawa K
Bone Marrow Transplant; 2011 Dec; 46(12):1557-65. PubMed ID: 21258423
[TBL] [Abstract][Full Text] [Related]
5. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers.
Bartik MM; Baumgartel-Scofield BA; Mokyr MB
Cancer Immunol Immunother; 1991; 34(2):79-89. PubMed ID: 1760820
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
8. NK cells in allogeneic bone marrow transplantation.
Voutsadakis IA
Cancer Immunol Immunother; 2003 Sep; 52(9):525-34. PubMed ID: 14627124
[TBL] [Abstract][Full Text] [Related]
9. Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2.
Bogyo D; Fondy SR; Finster L; Fondy C; Patil S; Fondy TP
Cancer Immunol Immunother; 1991; 32(6):400-5. PubMed ID: 1901032
[TBL] [Abstract][Full Text] [Related]
10. Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.
Eberlein TJ; Rosenstein M; Spiess P; Wesley R; Rosenberg SA
Cancer Immunol Immunother; 1982; 13(1):5-13. PubMed ID: 6984355
[TBL] [Abstract][Full Text] [Related]
11. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals.
Schirrmacher V
Cancer Immunol Immunother; 2014 Jun; 63(6):535-43. PubMed ID: 24610041
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells.
Weiss L; Or R; Slavin S; Naparstek E; Reich S; Abdul-Hai A
Cancer Immunol Immunother; 2004 Apr; 53(4):358-62. PubMed ID: 14605765
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
15. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of allogeneic antigen-specific T cells.
Riddell SR; Bleakley M; Nishida T; Berger C; Warren EH
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):9-12. PubMed ID: 16399578
[TBL] [Abstract][Full Text] [Related]
18. Cell therapy: achievements and perspectives.
Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
